

GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS

LOK SABHA

UNSTARRED QUESTION No. 1898

TO BE ANSWERED ON THE 14th March, 2017

Price Cut by NPPA

1898. SHRI B. SENGUTTUVAN:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) whether stent are sold in India at a profit ranging from 400 per cent to 500 percent and if so, the details thereof;
- (b) whether the National Pharmaceutical Pricing Authority has slashed the price of coronary stent by 75 per cent and if so, the details thereof;
- (c) whether the NPPA has capped the selling price of Drug Eluting Stents and Bioreabsorbable Vascular Scaffolds as well as those of Bare Metal Stents and if so, the details thereof; and
- (d) the proactive steps taken by the Government against hoarding and to ensure availability of stents in the market?

ANSWER

MINISTER OF STATE FOR CHEMICALS & FERTILIZERS, ROAD TRANSPORT & HIGHWAYS AND SHIPPING (SHRI MANSUKH L. MANDAVIYA)

(a to c): National Pharmaceuticals Pricing Authority (NPPA) notified the ceiling price of Coronary Stent vide its notification dated 13th February 2017 at INR 7,260/- for Bare Metal Stent and INR 29,600/- for Drug Eluting Stents (DES) including metallic DES and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable Stents. The average MRP before this notification was INR 45,100 for Bare Metal Stent (BMS) and INR 121,400 for Drug Eluting Stent (DES). Price regulation has brought down the prices of stents (BMS 74% and DES 85%).

(d): Government through NPPA is closely monitoring the situation and has alerted the State Governments and State Drugs Controllers to monitor the availability of stents. NPPA has also requested aggrieved persons to send verifiable information / complaints on help line number of NPPA, through online complaint mechanism (Pharma Jan Samadhan) or on Whatsapp. Industry has been apprised that all manufactures / importers are under legal obligation to maintain smooth production and supply of coronary stents of all brands which were available in the country before price cap. All State Governments and State Drug Controllers have been advised to exercise the power of entry, search and seizure as per Para 30 of Drugs Price Control Order (DPCO),2013 if manufacturers/importers/distributors try to create artificial shortage of stents.

XXXX